Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -13.50p -0.86% 1,550.00p 1,549.50p 1,550.50p 1,561.50p 1,541.00p 1,549.00p 575,610 16:35:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1,433.4 -546.4 -260.1 - 3,742.03

Hikma Pharmaceuticals Share Discussion Threads

Showing 1051 to 1074 of 1075 messages
Chat Pages: 43  42  41  40  39  38  37  36  35  34  33  32  Older
DateSubjectAuthorDiscuss
19/12/2018
08:40
Sector activity
robertball
12/11/2018
13:16
https://www.fiercepharma.com/manufacturing/dea-gives-some-pfizer-s-injected-narcotic-allotment-to-competitors-to-alleviate
bantam175
12/11/2018
08:13
Below where we were before the announcement now .. Nuts. IMHO it's only a matter of time before a return to the 100 and a rerating to around £24 ps. Hopefully followed by a making up with the FDA then who knows? Odd there always seems to be a big drop before a big surge. Downgrade from Peel Hunt this morning from add to hold, although they have actually raised their target price?
bantam175
10/11/2018
13:04
That was a kick
joshuam
09/11/2018
19:38
I suppose. I reckon half of any gain is given up. So long as trend is intact
robertball
09/11/2018
17:22
Profit taking on announcement and at an apparent resistance level I imagine, Robertball.
mayers
09/11/2018
09:19
Really what has happened?
robertball
08/11/2018
09:04
Hikma Pharmaceuticals said it was raising group full year guidance after solid performances from its injectibles and generics divisions. The global injectables business had offset increased competition in the US through the “breadth and resilience of our growing portfolio, good demand for recent launches and our ability to leverage our scale and flexibility to respond to market shortages”, the company said in a trading statement. Injectables revenue was now expected to be in the range of $825m - $850m and core injectables operating margin to be between 39% and 40%. Generics revenue was upgraded to $675m - to $700m with core operating margin to be in the low teens. The generics business continued to perform ahead of expectations, despite a challenging US retail market, with continued price erosion. “We have made good progress with our cost reduction initiatives, including the consolidation of our manufacturing and distribution facilities, and this is supporting the strong improvement in the profitability of our generics business this year,” Hikma said. The company added that it had signed an agreement with Vectura to develop and commercialise their Open, Inhale, Close (OIC) dry product inhaler (DPI) platform, including generic versions of GSK's five Ellipta DPI products. "The generic respiratory market is a key area of focus for Hikma. This agreement leverages the investment we have made and the experience we are gaining through our generic Advair Diskus development programme," it said. Hikma will make an upfront payment of $15m to Vectura with $5m payable on transfer of the first product to Hikma's manufacturing facility to enable clinical manufacturing. "Thereafter, Hikma will make milestone payments of up to $75m at various stages of development, including the delivery of pharmacokinetic clinical trials, pivotal clinical trials, ANDA submissions and FDA approvals," Hikma said. "On approval, Hikma will pay a share of distributable net profit of up to a mid-teen percentage for each portfolio product. Hikma will also pay sales milestones on the achievement of certain cumulative net sales targets. Vectura will contribute up to $70 million towards Hikma's development activities for the portfolio." "Vectura's contribution to the development costs will be deferred and made through a reduced profit share mechanism following commercial launch of the first product
broadwood
08/11/2018
08:55
Terrific trading statement with upped guidance and tie up with Vectura.
broadwood
07/11/2018
20:16
Investegate is reliable for dates
robertball
07/11/2018
10:22
sorry meant thurs
eentweedrie
06/11/2018
20:31
It's Thursday for trading stmt
robertball
06/11/2018
10:35
tomorrow in fact
eentweedrie
06/11/2018
09:37
Results soon
robertball
01/11/2018
08:12
Trading update next week
robertball
01/10/2018
07:51
After a pause.....
robertball
17/9/2018
09:22
Barclays reiterate their 1400 guidance today. What are they on?
bantam175
06/9/2018
15:08
Has Pfizer sorted their problems out?
robertball
21/8/2018
12:11
Traded no trades
gerrym two
21/8/2018
12:10
We said HIk would be back at 20 soon...it could get there today !! Will keep going in my view and on the back of a weak or at least a flat market.....what price does it have to get to get back into FT 100... or maybe it is ??I bought again at 1860p ...trades get the whole way up, my best trades share this year...by a distance.
gerrym two
20/8/2018
08:54
Back into profit with hik and I think there is more to come. Happy days. Suet
suetballs
15/8/2018
12:55
no. who from?
r ball
15/8/2018
12:38
What odds on a possible bid before the share price gets to high I wonder?
bantam175
15/8/2018
11:38
so good results on the back of Pfizer issues.
r ball
Chat Pages: 43  42  41  40  39  38  37  36  35  34  33  32  Older
Your Recent History
LSE
HIK
Hikma Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190117 20:10:38